Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 9:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 2,242 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: RNA sequencing Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Bacterial Genomic Sequencing in Overactive Bladder

NCT01642277
View directory record Official record
Conditions
Overactive Bladder
Interventions
Solifenacin
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 19, 2026, 9:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mindfulness-Based Art Therapy and Generation Z

NCT04834765
View directory record Official record
Conditions
Anxiety Depression
Interventions
Mindfulness-based art therapy, Art-only, Mindfulness-only
Other
Lead sponsor
Florida State University
Other
Eligibility
18 Years to 25 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 19, 2026, 9:06 AM EDT
Active, not recruiting Not applicable Interventional

REsynchronization Comparison In LBBB and Normal or Mildly Reduced VENTricular Function With CRT (REINVENT-CRT)

NCT05652218
View directory record Official record
Conditions
Left Ventricular Ejection Fraction, Heart Failure (HF), Left Bundle-Branch Block
Interventions
LB-CRT, BIV-CRT
Device
Lead sponsor
Inova Health Care Services
Other
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Durham, North Carolina • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 19, 2026, 9:06 AM EDT
Completed Phase 3 Interventional Results available

Study of Diagnostic Performance of [18F]CTT1057 in BCR

NCT04838613
View directory record Official record
Conditions
Prostatic Neoplasms, Prostate Cancer, Recurrence
Interventions
[18F]CTT1057, [68Ga]Ga-PSMA-11
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 19, 2026, 9:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine

NCT03078556
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Dolutegravir, Lamivudine, Dolutegravir + Lamivudine FDC Formulation 1, Dolutegravir + Lamivudine FDC Formulation 2
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Oct 19, 2026, 9:06 AM EDT
Terminated Not applicable Interventional

Building Equitable Linkages With Interprofessional Education Valuing Everyone

NCT06483022
View directory record Official record
Conditions
Pregnancy Related, Postpartum, Pain
Interventions
BELIEVE IPE Training, Usual Care
Behavioral · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 19, 2026, 9:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy Participants

NCT04991571
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Zibotentan (Treatment A), Dapagliflozin (Treatment A), Zibotentan/Dapagliflozin - Formulation 1 (Treatment B), Zibotentan/Dapagliflozin - Formulation 2 (Treatment C)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 19, 2026, 9:06 AM EDT
Recruiting No phase listed Observational

An Exosomal microRNA Signature for Preoperative Staging in Colon Cancer

NCT07255729
View directory record Official record
Conditions
Colon Cancer
Interventions
Diagnostic Test: EXPOSE assay（Small RNA-seq of exosomal miRNAs）, Diagnostic Test: EXPOSE RT-qPCR panel
Diagnostic Test
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 19, 2026, 9:06 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia

NCT02910102
View directory record Official record
Conditions
Alzheimer's Disease, Dementia With Lewy Bodies, Parkinson's Disease Dementia
Interventions
RVT-101 35 mg, Placebo
Drug
Lead sponsor
Axovant Sciences Ltd.
Industry
Eligibility
50 Years to 89 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
11
States / cities
Phoenix, Arizona • Simi Valley, California • Temecula, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2020 · Synced Oct 19, 2026, 9:06 AM EDT
Not listed Not applicable Interventional

Sequence of Symptom Change During AUD or PTSD Treatment for Comorbid PTSD/AUD

NCT01663337
View directory record Official record
Conditions
PTSD, Alcohol Abuse, Alcohol Dependence
Interventions
Cognitive Processing Therapy (CPT), Relapse Prevention (RP)
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 19, 2026, 9:06 AM EDT
Completed Phase 2 Interventional Results available

Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.

NCT03257995
View directory record Official record
Conditions
Asthma
Interventions
Indacaterol maleate, Indacaterol acetate, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
North Dartmouth, Massachusetts • St Louis, Missouri • Skillman, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 19, 2026, 9:06 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

NCT03861481
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Interventions
Rozanolixizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Phoenix, Arizona • Los Angeles, California • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 19, 2026, 9:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants

NCT07190430
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PF-08049820, Midazolam, Dabigatran Etexilate, Portia (EE and LN) or equivalent oral tablet
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 19, 2026, 9:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers

NCT01463228
View directory record Official record
Conditions
Healthy
Interventions
A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets), B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
19 Years to 55 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 22, 2012 · Synced Oct 19, 2026, 9:06 AM EDT
Not yet recruiting Not applicable Interventional

Osteopathic Manipulative Treatment for Children With Chronic or Recurrent Otitis Media

NCT07639775
View directory record Official record
Conditions
Otitis Media, Otitis Media Effusion, Otitis Media Recurrent, Otitis Media With Effusion in Children, Otitis Media Chronic, Otitis Media in Children, Tympanostomy Tube Insertion, Osteopathic Manipulative Treatment (OMT)
Interventions
Experimental Osteopathic Manipulative Treatment (OMT) Protocol, Control Osteopathic Manipulative Treatment (OMT) Protocol
Other
Lead sponsor
Sarah Vidal
Other
Eligibility
6 Months to 6 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Lynchburg, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 19, 2026, 9:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Divarasib in Healthy Participants

NCT06835465
View directory record Official record
Conditions
Healthy Participants
Interventions
Divarasib, Rifampin
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 19, 2026, 9:06 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Does Style Matter: Comparison of Moderate- to Low-intensity Styles of Yoga

NCT07638267
View directory record Official record
Conditions
Insomnia, Health Adult Subjects, Insomnia Disorder, Heart Health Markers
Interventions
Vinyasa yoga, Gentle yoga, Non-active control
Behavioral · Other
Lead sponsor
Caitlin Cheruka
Other
Eligibility
18 Years to 40 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 19, 2026, 9:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Crossover Bioequivalence Study of Quetiapine Fumarate 25 mg Tablets Under Fasted Conditions

NCT01570907
View directory record Official record
Conditions
Treatment for Bipolar I Disorder
Interventions
Quetiapine Fumarate
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 19, 2026, 9:06 AM EDT
Completed Phase 1 Interventional

A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors

NCT02626234
View directory record Official record
Conditions
cMET-dysregulated Advanced Solid Tumors
Interventions
INC280, digoxin, rosuvastatin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Atlanta, Georgia • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Oct 19, 2026, 9:06 AM EDT
Completed Phase 2 Interventional Results available

A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy

NCT01006122
View directory record Official record
Conditions
Excessive Daytime Sleepiness, Narcolepsy
Interventions
Placebo, PF-03654746
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
21
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 19, 2026, 9:06 AM EDT
Completed Not applicable Interventional Results available

Low Field Magnetic Stimulation for Treatment Resistant Depression

NCT01944644
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Active Low Field Magnetic Stimulation, Sham Low Field Magnetic Stimulation
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Oct 19, 2026, 9:06 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation

NCT02709109
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-371 + HS, Hypertonic saline, Placebo, Orkambi, VX-371
Drug
Lead sponsor
Parion Sciences
Industry
Eligibility
12 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
30
States / cities
Little Rock, Arkansas • Oakland, California • Gainesville, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Oct 19, 2026, 9:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Acute Intermittent Hypoxia on Sensory Function in Healthy Adults

NCT03283072
View directory record Official record
Conditions
Sensitivity
Interventions
Intervention 1, Intervention 2, Intervention 3, Intervention 4 (sham)
Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 40 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 19, 2026, 9:06 AM EDT
Completed Phase 2 Interventional Results available

AD109 Dose Finding in Mild to Moderate OSA

NCT04631107
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
AD109 dose1- A, AD109 dose2- B, Placebo- C
Drug
Lead sponsor
Apnimed
Industry
Eligibility
25 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
San Diego, California • Atlanta, Georgia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Oct 19, 2026, 9:06 AM EDT